1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Erytech Could Launch Several New Studies Following Pancreatic Cancer PhII Success

 
• By Lucie Ellis-Taitt

Erytech's lead therapy has shown strong anti-cancer activity in pancreatic cancer, on top of the hematological indications it is already targeting in late-stage trials, spelling good news for the French firm to pursue more studies in other oncology indications such as ovarian cancer.

Cancer cells
Erytech's positive pancreatic cancer data could push the company towards other solid tumor indications

French biotech Erytech Pharma SA is likely to pursue expedited regulatory submissions for its second-line pancreatic cancer therapy, eryaspase, on the back of strong topline Phase IIb data; as well as assess its options in other solid tumor indications now that the treatment has demonstrated positive effects in oncological and hematological cancers.

Analysts at Jefferies are predicting peak worldwide sales of $500m for eryaspase and have given the therapy an 80% probability...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

More from R&D

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.